Antibody gene transfer offers a promising solution to the high cost and frequent administration of monoclonal antibodies (mAbs), enabling the body to produce its own drugs economically and sustainably. This review addresses the challenges faced by antibody therapies, including economic and environmental impacts, as well as patient-related issues such as efficacy and tolerance. We propose that direct in vivo protein production, or autologous production, via plasmid DNA (pDNA) injection may address some of these challenges. This pDNA-based strategy provides a cost-effective alternative while maintaining flexibility and adaptability for various proteins, making it suitable for a wide range of pathological contexts. Additionally, gene therapy with plasmids could reduce the need for frequent injections, improving patient compliance. In this review, we provide an overview of the pioneering studies that introduced the use of pDNA for in vivo protein production. We focus on key factors for successful autologous production, such as plasmid design, vectorization, and methods of administration. Finally, we explore various applications where autologous production could serve as a promising alternative for therapeutic antibody treatments.
Get full access to this article
View all access options for this article.
References
1.
El AbdY, TabllA, SmolicR, et al.Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies—SARS CoV-2 as an example. Hum Antibodies, 2022; 30(1):15–24; doi: 10.3233/HAB-211513
2.
ChiuML, GouletDR, TeplyakovA, et al.Antibody structure and function: The basis for engineering therapeutics. Antibodies (Basel), 2019; 8(4):55; doi: 10.3390/antib8040055
ChamesP, Van RegenmortelM, WeissE, et al.Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol, 2009; 157(2):220–233; doi: 10.1111/j.1476-5381.2009.00190.x
5.
Abu LilaAS, KiwadaH, IshidaT. The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage. J Control Release, 2013; 172(1):38–47; doi: 10.1016/j.jconrel.2013.07.026
6.
WhiteheadHS, FrenchCE, CaldwellDM, et al.A systematic review of communication interventions for countering vaccine misinformation. Vaccine, 2023; 41(5):1018–1034; doi: 10.1016/j.vaccine.2022.12.059
7.
AlbertsB, JohnsonA, LewisJ, et al.From DNA to RNA. In: Molecular Biology of the Cell. 4th Edition. Garland Science; 2002.
8.
MinchinS, LodgeJ. Understanding biochemistry: Structure and function of nucleic acids. Essays Biochem, 2019; 63(4):433–456; doi: 10.1042/EBC20180038
ArabiF, MansouriV, AhmadbeigiN. Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother, 2022; 153:113324; doi: 10.1016/j.biopha.2022.113324
WolffJA, MaloneRW, WilliamsP, et al.Direct gene transfer into mouse muscle in vivo. Science, 1990; 247(4949 Pt 1):1465–1468; doi: 10.1126/science.1690918
16.
WolffJA, LudtkeJJ, AcsadiG, et al.Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet, 1992; 1(6):363–369; doi: 10.1093/hmg/1.6.363
17.
JiaoS, WilliamsP, BergRK, et al.Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther, 1992; 3(1):21–33; doi: 10.1089/hum.1992.3.1-21
18.
OwjiH, NezafatN, NegahdaripourM, et al.A comprehensive review of signal peptides: Structure, roles, and applications. Eur J Cell Biol, 2018; 97(6):422–441; doi: 10.1016/j.ejcb.2018.06.003
19.
ZhangC, FuY, ZhengW, et al.Enhancing the antibody production efficiency of Chinese hamster ovary cells through improvement of disulfide bond folding ability and apoptosis resistance. Cells, 2024; 13(17):1481; doi: 10.3390/cells13171481
20.
WiedemannC, KumarA, LangA, et al.Cysteines and disulfide bonds as structure-forming units: Insights from different domains of life and the potential for characterization by NMR. Front Chem, 2020; 8:280; doi: 10.3389/fchem.2020.00280
HelbleM, ChuJ, FlowersK, et al.Structure and sequence engineering approaches to improve in vivo expression of nucleic acid-delivered antibodies. Mol Ther, 2025; 33(1):152–167; doi: 10.1016/j.ymthe.2024.11.030
23.
HenggeUR, DexlingB, MirmohammadsadeghA. Safety and pharmacokinetics of naked plasmid DNA in the skin: Studies on dissemination and ectopic Expression. J Invest Dermatol, 2001; 116(6):979–982; doi: 10.1046/j.1523-1747.2001.01341.x
WirthT, HedmanM, MäkinenK, et al.Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy. Curr Drug Saf, 2006; 1(3):253–257; doi: 10.2174/157488606777934440
26.
KriegAM, YiA-K, MatsonS, et al.CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 1995; 374(6522):546–549; doi: 10.1038/374546a0
27.
BazzaniRP, CaiY, HebelHL, et al.The significance of plasmid DNA preparations contaminated with bacterial genomic DNA on inflammatory responses following delivery of lipoplexes to the murine lung. Biomaterials, 2011; 32(36):9854–9865; doi: 10.1016/j.biomaterials.2011.08.092
28.
SakuraiH, KawabataK, SakuraiF, et al.Innate immune response induced by gene delivery vectors. Int J Pharm, 2008; 354(1–2):9–15; doi: 10.1016/j.ijpharm.2007.06.012
29.
TousignantJD, GatesAL, IngramLA, et al.Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther, 2000; 11(18):2493–2513; doi: 10.1089/10430340050207984
30.
GasparV, Melo-DiogoDD, CostaE, et al.Minicircle DNA vectors for gene therapy: Advances and applications. Expert Opin Biol Ther, 2015; 15(3):353–379; doi: 10.1517/14712598.2015.996544
31.
KayMA, HeC-Y, ChenZ-Y. A robust system for production of minicircle DNA vectors. Nat Biotechnol, 2010; 28(12):1287–1289; doi: 10.1038/nbt.1708
32.
ChenZ-Y, HeC-Y, EhrhardtA, et al.Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther, 2003; 8(3):495–500; doi: 10.1016/S1525-0016(03)00168-0
Anonymous. Guidance for industry: Considerations for plasmid DNA vaccines for infectious disease indications. Biotechnol Law Rep, 2007; 26(6):641–648; doi: 10.1089/blr.2007.9905
Pham-HuyA, TopKA, ConstantinescuC, et al.The use and impact of monoclonal antibody biologics during pregnancy. CMAJ, 2021; 193(29):E1129–E1136; doi: 10.1503/cmaj.202391
37.
HollevoetK, DeclerckPJ. State of play and clinical prospects of antibody gene transfer. J Transl Med, 2017; 15(1):131; doi: 10.1186/s12967-017-1234-4
38.
StraathofKC, PulèMA, YotndaP, et al.An inducible caspase 9 safety switch for T-cell therapy. Blood, 2005; 105(11):4247–4254; doi: 10.1182/blood-2004-11-4564
39.
YuanY, RenH, LiY, et al.Cell-to-cell variability in inducible Caspase9-mediated cell death. Cell Death Dis, 2022; 13(1):34; doi: 10.1038/s41419-021-04468-z
40.
ZhouX, DottiG, KranceRA, et al.Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood, 2015; 125(26):4103–4113; doi: 10.1182/blood-2015-02-628354
41.
GargettT, BrownMP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol, 2014; 5:235; doi: 10.3389/fphar.2014.00235
42.
BouquetL, Bôle-RichardE, WardaW, et al.RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells. Gene Ther, 2023; 30(9):706–713; doi: 10.1038/s41434-023-00404-2
LiA, LeeCM, HurleyAE, et al.A self-deleting AAV-CRISPR system for in vivo genome editing. Mol Ther Methods Clin Dev, 2019; 12:111–122; doi: 10.1016/j.omtm.2018.11.009
45.
ErtlHCJ. Mitigating serious adverse events in gene therapy with AAV vectors: Vector dose and immunosuppression. Drugs, 2023; 83(4):287–298; doi: 10.1007/s40265-023-01836-1
46.
DowLE, FisherJ, O’RourkeKP, et al.Inducible in vivo genome editing with CRISPR/Cas9. Nat Biotechnol, 2015; 33(4):390–394; doi: 10.1038/nbt.3155
47.
MüllerK, NaumannS, WeberW, et al.Optogenetics for gene expression in mammalian cells. Biol Chem, 2015; 396(2):145–152; doi: 10.1515/hsz-2014-0199
PolesskayaO, BaranovaA, BuiS, et al.Optogenetic regulation of transcription. BMC Neurosci, 2018; 19(Suppl 1):12; doi: 10.1186/s12868-018-0411-6
50.
MuenchP, FiumaraM, SouthernN, et al.A modular toolbox for the optogenetic deactivation of transcription. Nucleic Acids Res, 2025; 53(3):gkae1237; doi: 10.1093/nar/gkae1237
51.
YeH, FusseneggerM. Optogenetic medicine: Synthetic therapeutic solutions precision-guided by light. Cold Spring Harb Perspect Med, 2019; 9(9):a034371; doi: 10.1101/cshperspect.a034371
RamamoorthM, NarvekarA. Non viral vectors in gene therapy—An overview. J Clin Diagn Res, 2015; 9(1):GE01–GE06; doi: 10.7860/JCDR/2015/10443.5394
54.
FumotoS, YamamotoT, OkamiK, et al.Understanding in vivo fate of nucleic acid and gene medicines for the rational design of drugs. Pharmaceutics, 2021; 13(2):159; doi: 10.3390/pharmaceutics13020159
55.
Hosseini-KharatM, BremmellKE, Grubor-BaukB, et al.Enhancing non-viral DNA delivery systems: Recent advances in improving efficiency and target specificity. J Control Release, 2025; 378:170–194; doi: 10.1016/j.jconrel.2024.12.002
56.
KawabataK, TakakuraY, HashidaM. The fate of plasmid DNA after intravenous injection in mice: Involvement of scavenger receptors in its hepatic uptake. Pharm Res, 1995; 12(6):825–830; doi: 10.1023/a:1016248701505
LatzE, SchoenemeyerA, VisintinA, et al.TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol, 2004; 5(2):190–198; doi: 10.1038/ni1028
59.
HollevoetK, ThomasD, CompernolleG, et al.Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model. Front Oncol, 2022; 12:1017612; doi: 10.3389/fonc.2022.1017612
60.
HellerLC, HellerR. In vivo electroporation for gene therapy. Hum Gene Ther, 2006; 17(9):890–897; doi: 10.1089/hum.2006.17.890
61.
PislaruSV, PislaruC, KinnickRR, et al.Optimization of ultrasound-mediated gene transfer: Comparison of contrast agents and ultrasound modalities. Eur Heart J, 2003; 24(18):1690–1698; doi: 10.1016/S0195-668X(03)00469-X
62.
WangL, WeiX, LiuH, et al.Nanomaterial-mediated photoporation for intracellular delivery. Acta Biomater, 2023; 157:24–48; doi: 10.1016/j.actbio.2022.12.050
63.
SizikovAA, NikitinPI, NikitinMP. Magnetofection in vivo by nanomagnetic carriers systemically administered into the bloodstream. Pharmaceutics, 2021; 13(11):1927; doi: 10.3390/pharmaceutics13111927
64.
LiS. Delivery of DNA into tumors. Methods Mol Biol, 2008; 423:311–318; doi: 10.1007/978-1-59745-194-9_23
65.
WatkinsC, HopkinsJ, HarkissG. Reporter gene expression in dendritic cells after gene gun administration of plasmid DNA. Vaccine, 2005; 23(33):4247–4256; doi: 10.1016/j.vaccine.2005.03.023
66.
MostaghaciB, LoretzB, LehrC-M. Calcium phosphate system for gene delivery: Historical background and emerging opportunities. Curr Pharm Des, 2016; 22(11):1529–1533; doi: 10.2174/1381612822666151210123859
67.
CarvalhoAM, CordeiroRA, FanecaH. Silica-based gene delivery systems: From design to therapeutic applications. Pharmaceutics, 2020; 12(7):649; doi: 10.3390/pharmaceutics12070649
68.
EliyahuH, BarenholzY, DombA. Polymers for DNA delivery. Molecules, 2005; 10(1):34–64; doi: 10.3390/10010034
69.
FelgnerPL, GadekTR, HolmM, et al.Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A, 1987; 84(21):7413–7417; doi: 10.1073/pnas.84.21.7413
70.
DavidS, PassiraniC, CarmoyN, et al.DNA nanocarriers for systemic administration: Characterization and in vivo bioimaging in healthy mice. Mol Ther Nucleic Acids, 2013; 2(1):e64; doi: 10.1038/mtna.2012.56
71.
YinH, MoultonHM, BettsC, et al.Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther, 2010; 18(10):1822–1829; doi: 10.1038/mt.2010.151
MurakamiT, SunadaY. Plasmid DNA gene therapy by electroporation: Principles and recent advances. Curr Gene Ther, 2011; 11(6):447–456; doi: 10.2174/156652311798192860
74.
Denoth-LippunerA, RoyallLN, Gonzalez-BohorquezD, et al.Injection and electroporation of plasmid DNA into human cortical organoids. STAR Protoc, 2022; 3(1):101129; doi: 10.1016/j.xpro.2022.101129
75.
CuypersM-L, GeukensN, HollevoetK, et al.Exploring the fate of antibody-encoding pDNA after intramuscular electroporation in mice. Pharmaceutics, 2023; 15(4):1160; doi: 10.3390/pharmaceutics15041160
76.
NsairatH, AlshaerW, OdehF, et al.Recent advances in using liposomes for delivery of nucleic acid-based therapeutics. OpenNano, 2023; 11:100132; doi: 10.1016/j.onano.2023.100132
77.
GregoriadisG, SaffieR, HartSL. High yield incorporation of plasmid DNA within liposomes: Effect on DNA integrity and transfection efficiency. J Drug Target, 1996; 3(6):469–475; doi: 10.3109/10611869609015966
78.
KumarP, YadavN, ChaudharyB, et al.Lipid nanocapsule: A novel approach to drug delivery system formulation development. Curr Pharm Biotechnol, 2024; 25(3):268–284; doi: 10.2174/1389201024666230523114350
79.
HuynhNT, PassiraniC, SaulnierP, et al.Lipid nanocapsules: A new platform for nanomedicine. Int J Pharm, 2009; 379(2):201–209; doi: 10.1016/j.ijpharm.2009.04.026
80.
DavidS, MontierT, CarmoyN, et al.Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model. J Gene Med, 2012; 14(12):769–775; doi: 10.1002/jgm.2683
81.
DavidS, CarmoyN, ResnierP, et al.In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. Int J Pharm, 2012; 423(1):108–115; doi: 10.1016/j.ijpharm.2011.06.031
82.
ChenJ, XuY, ZhouM, et al.Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. Proc Natl Acad Sci U S A, 2023; 120(50):e2309472120; doi: 10.1073/pnas.2309472120
83.
SunD, LuZ-R. Structure and function of cationic and ionizable lipids for nucleic acid delivery. Pharm Res, 2023; 40(1):27–46; doi: 10.1007/s11095-022-03460-2
84.
ScalzoS, SantosAK, FerreiraHA, et al.Ionizable lipid nanoparticle-mediated delivery of plasmid DNA in cardiomyocytes. Int J Nanomedicine, 2022; 17:2865–2881; doi: 10.2147/IJN.S366962
85.
ZengC, ZhangC, WalkerPG, et al.Formulation and delivery technologies for mRNA vaccines. In: mRNA Vaccines. (YuD, PetschB eds). Current Topics in Microbiology and Immunology Springer International Publishing: Cham; 2020; pp. 71–110; doi: 10.1007/82_2020_217
86.
KimJ, De JesusO. Medication Routes of Administration. 2023 Aug 23. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island (FL); 2025.
KumariN, SiddhantaK, PanjaS, et al.Oral delivery of nucleic acid therapies for local and systemic action. Pharm Res, 2023; 40(1):107–122; doi: 10.1007/s11095-022-03415-7
89.
WangQ, BuC, DaiQ, et al.Recent progress in nucleic acid pulmonary delivery toward overcoming physiological barriers and improving transfection efficiency. Adv Sci (Weinh), 2024; 11(18):e2309748; doi: 10.1002/advs.202309748
90.
ButtrickPM, KassA, KitsisRN, et al.Behavior of genes directly injected into the rat heart in vivo. Circ Res, 1992; 70(1):193–198; doi: 10.1161/01.RES.70.1.193
91.
HenggeUR, WalkerPS, VogelJC. Expression of naked DNA in human, pig, and mouse skin. J Clin Invest, 1996; 97(12):2911–2916; doi: 10.1172/JCI118750
92.
SikesML, O’MalleyBW, FinegoldMJ, et al.In vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. Hum Gene Ther, 1994; 5(7):837–844; doi: 10.1089/hum.1994.5.7-837
93.
HickmanMA, MaloneRW, SihTR, et al.Hepatic gene expression after direct DNA injection. Adv Drug Deliv Rev, 1995; 17(3):265–271; doi: 10.1016/0169-409X(95)00060-K
94.
YovandichJ, O’MalleyB, SikesM, et al.Gene transfer to synovial cells by intra-articular administration of plasmid DNA. Hum Gene Ther, 1995; 6(5):603–610; doi: 10.1089/hum.1995.6.5-603
95.
SchwartzB, BenoistC, AbdallahB, et al.Lipospermine-based gene transfer into the newborn mouse brain is optimized by a low lipospermine/DNA charge ratio. Hum Gene Ther, 1995; 6(12):1515–1524; doi: 10.1089/hum.1995.6.12-1515
96.
ConryRM, LoBuglioAF, KantorJ, et al.Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res, 1994; 54(5):1164–1168.
97.
YangJ. Intratumoral Injection of Naked DNA. In: Gene Therapy of Cancer. Humana Press: New Jersey; 2000; pp. 313–321; doi: 10.1385/1-59259-086-1:313
98.
MiaoCH, ThompsonAR, LoebK, et al.Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther, 2001; 3(6):947–957; doi: 10.1006/mthe.2001.0333
BüningH, MorganM, SchambachA. Skeletal muscle-directed gene therapy: Hijacking the fusogenic properties of muscle cells. Signal Transduct Target Ther, 2023; 8(1):340; doi: 10.1038/s41392-023-01584-4
105.
RollandAP, MumperRJ. Plasmid delivery to muscle: Recent advances in polymer delivery systems. Adv Drug Deliv Rev, 1998; 30(1–3):151–172; doi: 10.1016/s0169-409x(97)00113-0
106.
MonteroDA, VidalRM, VelascoJ, et al.Two centuries of vaccination: Historical and conceptual approach and future perspectives. Front Public Health, 2023; 11:1326154; doi: 10.3389/fpubh.2023.1326154
UlmerJB, DonnellyJJ, ParkerSE, et al.Heterologous protection against influenza by injection of DNA encoding a viral protein. Science, 1993; 259(5102):1745–1749; doi: 10.1126/science.8456302
109.
DavisHL, MichelM-L, WhalenRG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet, 1993; 2(11):1847–1851; doi: 10.1093/hmg/2.11.1847
110.
DavisHL, McCluskieMJ, GerinJL, et al.DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci U S A, 1996; 93(14):7213–7218; doi: 10.1073/pnas.93.14.7213
111.
KutzlerMA, WeinerDB. DNA vaccines: Ready for prime time? Nat Rev Genet, 2008; 9(10):776–788; doi: 10.1038/nrg2432
112.
DauphinG, ZientaraS. West Nile virus: Recent trends in diagnosis and vaccine development. Vaccine, 2007; 25(30):5563–5576; doi: 10.1016/j.vaccine.2006.12.005
113.
LongA, RichardJ, HawleyL, et al.Transmission potential of infectious hematopoietic necrosis virus in APEX-IHN®-vaccinated Atlantic salmon. Dis Aquat Organ, 2017; 122(3):213–221; doi: 10.3354/dao03076
FlingaiS, PlummerEM, PatelA, et al.Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep, 2015; 5(1):12616; doi: 10.1038/srep12616
116.
McNeeA, SmithTRF, HolzerB, et al.Establishment of a pig influenza challenge model for evaluation of monoclonal antibody delivery platforms. J Immunol, 2020; 205(3):648–660; doi: 10.4049/jimmunol.2000429
117.
EsquivelRN, PatelA, KudchodkarSB, et al.In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus. Mol Ther, 2019; 27(5):974–985; doi: 10.1016/j.ymthe.2019.03.005
WinkleM, El-DalySM, FabbriM, et al.Noncoding RNA therapeutics—Challenges and potential solutions. Nat Rev Drug Discov, 2021; 20(8):629–651; doi: 10.1038/s41573-021-00219-z
120.
CrossD, BurmesterJK. Gene therapy for cancer treatment: Past, present and future. Clin Med Res, 2006; 4(3):218–227; doi: 10.3121/cmr.4.3.218
121.
Martínez-PuenteDH, Pérez-TrujilloJJ, Zavala-FloresLM, et al.Plasmid DNA for therapeutic applications in cancer. Pharmaceutics, 2022; 14(9):1861; doi: 10.3390/pharmaceutics14091861
122.
LopesA, VandermeulenG, PréatV. Cancer DNA vaccines: Current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res, 2019; 38(1):146; doi: 10.1186/s13046-019-1154-7
123.
ChoiD-H, WooJK, ChoiY, et al.A novel chimeric DNA vaccine: Enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene. Mol Med Rep, 2011; 4(5):885–890; doi: 10.3892/mmr.2011.525
124.
PandyaA, ShahY, KothariN, et al.The future of cancer immunotherapy: DNA vaccines leading the way. Med Oncol, 2023; 40(7):200; doi: 10.1007/s12032-023-02060-3
125.
GaoF-S, ZhanY-T, WangX-D, et al.Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model. Immunopharmacol Immunotoxicol, 2018; 40(4):353–357; doi: 10.1080/08923973.2018.1498099
126.
LiuX, YangY, ZhengX, et al.Enhanced anti-tumor efficacy through a combination of intramuscularly expressed DNA vaccine and plasmid-encoded PD-1 antibody. Front Immunol, 2023; 14:1169850; doi: 10.3389/fimmu.2023.1169850
127.
ZahaviD, WeinerL. Monoclonal antibodies in cancer therapy. Antibodies (Basel), 2020; 9(3):34; doi: 10.3390/antib9030034
128.
PatelA, ParkDH, DavisCW, et al.In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against ebolavirus infection in a mouse model. Cell Rep, 2018; 25(7):1982–1993.e4; doi: 10.1016/j.celrep.2018.10.062
129.
KimH, DanishmalikSN, HwangH, et al.Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2. Cancer Gene Ther, 2016; 23(10):341–347; doi: 10.1038/cgt.2016.37
130.
MuthumaniK, MarninL, KudchodkarSB, et al.Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunol Immunother, 2017; 66(12):1577–1588; doi: 10.1007/s00262-017-2042-7
131.
DuperretEK, TrautzA, StoltzR, et al.Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo. Cancer Res, 2018; 78(22):6363–6370; doi: 10.1158/0008-5472.CAN-18-1429
132.
KünnapuuK, VeimanK-L, PoroskL, et al.Tumor gene therapy by systemic delivery of plasmid DNA with cell-penetrating peptides. FASEB Bioadv, 2019; 1(2):105–114; doi: 10.1096/fba.1026
133.
De VisserKE, JoyceJA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 2023; 41(3):374–403; doi: 10.1016/j.ccell.2023.02.016
134.
Montaño-SamaniegoM, Bravo-EstupiñanDM, Méndez-GuerreroO, et al.Strategies for targeting gene therapy in cancer cells with tumor-specific promoters. Front Oncol, 2020; 10:605380; doi: 10.3389/fonc.2020.605380
135.
CockfieldSM, RamassarV, UrmsonJ, et al.Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cells to release IFN-gamma. J Immunol, 1989; 142(4):1120–1128; doi: 10.4049/jimmunol.142.4.1120
136.
Prud’hommeGJ, ChangY. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther, 1999; 6(5):771–777; doi: 10.1038/sj.gt.3300879
137.
DurieuxA-C, BonnefoyR, ManissolleC, et al.High-efficiency gene electrotransfer into skeletal muscle: Description and physiological applicability of a new pulse generator. Biochem Biophys Res Commun, 2002; 296(2):443–450; doi: 10.1016/S0006-291X(02)00901-4
138.
RimYA, YiH, KimY, et al.Self in vivo production of a synthetic biological drug CTLA4Ig using a minicircle vector. Sci Rep, 2014; 4(1):6935; doi: 10.1038/srep06935
139.
YiH, KimY, KimJ, et al.A new strategy to deliver synthetic protein drugs: Self-reproducible biologics using minicircles. Sci Rep, 2014; 4(1):5961; doi: 10.1038/srep05961
140.
LimSW, KimYK, ParkN, et al.Application of minicircle technology of self-reproducing synthetic protein drugs in preventing skin allograft rejection. Ann Transplant, 2015; 20:430–440; doi: 10.1265/9/AOT.893828
141.
PangX, MaF, ZhangP, et al.Treatment of human B-cell lymphomas using minicircle DNA vector expressing anti-CD3/CD20 in a mouse model. Hum Gene Ther, 2017; 28(2):216–225; doi: 10.1089/hum.2016.122
142.
ZhaoJ, ChenG, PangX, et al.Calcium phosphate nanoneedle based gene delivery system for cancer genetic immunotherapy. Biomaterials, 2020; 250:120072; doi: 10.1016/j.biomaterials.2020.120072
143.
PangX, ChenG, HuangP, et al.Anticancer effects of a single intramuscular dose of a minicircle DNA vector expressing anti-CD3/CD20 in a xenograft mouse model. Mol Ther Oncolytics, 2022; 24:788–798; doi: 10.1016/j.omto.2022.02.014
144.
LimSW, ShinYJ, CuiS, et al.Therapeutic effect of multiple functional minicircle vector encoding anti-CD25/IL-10/CXCR3 in allograft rejection model. Korean J Intern Med, 2022; 37(5):1031–1049; doi: 10.3904/kjim.2021.299
145.
ChenG, ZengL, BiB, et al.Engineering bifunctional calcium alendronate gene‐delivery nanoneedle for synergistic chemo/immuno‐therapy against HER2 positive ovarian cancer. Adv Sci (Weinh), 2023; 10(14):e2204654; doi: 10.1002/advs.202204654
146.
KimY, YiH, JungH, et al.A dual target-directed agent against interleukin-6 receptor and tumor necrosis factor α ameliorates experimental arthritis. Sci Rep, 2016; 6(1):20150; doi: 10.1038/srep20150
147.
SudaH, MurakamiA, KagaT, et al.Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther, 2014; 12(10):1145–1156; doi: 10.1586/14779072.2014.955850
148.
PratherKJ, SagarS, MurphyJ, et al.Industrial scale production of plasmid DNA for vaccine and gene therapy: Plasmid design, production, and purification. Enzyme Microb Technol, 2003; 33(7):865–883; doi: 10.1016/S0141-0229(03)00205-9
